Alessia Cacciatore

Alessia Cacciatore

Auto-generated profile, based on publicly available information

Alessia Cacciatore

Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona, Switzerland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAlessia Cacciatore
Alessia Cacciatore
DSDheeraj Shinde
Dheeraj Shinde
CMCarola Musumeci
Carola Musumeci
GSGiada Sandrini
Giada Sandrini
Luca GuarreraLuca Guarrera
Luca Guarrera
Giuseppina CarboneGiuseppina Carbone
Giuseppina Carbone
Castration-resistant prostate cancer (CRPC) is a frequently occurring disease with adverse clinical outcomes and limited therapeutic options. Here, we identify methionine adenosyltransferase 2a (MAT2A) as a critical driver of the androgen-indifferent state in ERG fusion-positive CRPC. MAT2A is upregulated in CRPC and cooperates with ERG in promoting cell plasticity, stemness and tumorigenesis. RNA, ATAC and ChIP-sequencing coupled with histone post-translational modification analysis by mass spectrometry show that MAT2A broadly impacts the transcriptional and epigenetic landscape. MAT2A enhances H3K4me2 at multiple genomic sites, promoting the expression of pro-tumorigenic non-canonical AR target genes. Genetic and pharmacological inhibition of MAT2A reverses the transcriptional and epigenetic remodeling in CRPC models and improves the response to AR and EZH2 inhibitors. These data reveal a role of MAT2A in epigenetic reprogramming and provide a proof of concept for testing MAT2A inhibitors in CRPC patients to improve clinical responses and prevent treatment resistance.